Aduro Biotech

740 Heinz Avenue
Berkeley
California
94710
United States

Tel: 510-848-4800

Show jobs for this employer

About Aduro Biotech

Aduro Biotech, Inc. is a Berkeley, California-based immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases.

Aduro's three proprietary technology platforms, Live, Attenuated Double-Deleted Listeria (LADD), STING Pathway Activators, and B-select monoclonal antibodies, are designed to harness the body's natural immune system. Our extensive pipeline of product candidates derived from these platforms are currently being investigated in a variety of cancer indications and have the potential to expand into autoimmune and infectious diseases.

Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, gastric/esophageal, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor.

Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas.

Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development, including BION-1301, an anti-APRIL antibody. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.

Learn more at www.aduro.com.
 

Aduro Biotech. Pioneering Immunotherapy. Transforming Lives.

148 articles with Aduro Biotech

  • Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the closing of its merger with Aduro Biotech, Inc. and $115 million priva

  • Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced the results for the three proposals considered and voted upon by its stockholders at its Special Meeting on October 1, 2020.

  • Aduro Biotech, Inc., a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation Inducing Ligand and Stimulator of Interferon Genes pathways for the treatment of cancer, autoimmune and inflammatory diseases, provided a business update and reported financial results for the second quarter ended June 30, 2020.

  • It was a busy week for clinical trial updates. Here’s a look.
  • Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the first patient with IgA nephropathy has been dosed in a Phase 1 clinical trial of BION-1301, an investigational humanized IgG4 monoclonal

  • As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
  • BION-1301 was well-tolerated, with no serious adverse events (SAEs), treatment discontinuations or events meeting stopping criteria, across a wide range of doses Pharmacokinetics (PK) of BION-1301 were generally dose-proportional with an estimated half-life of 33 days, suggesting the potential for monthly dosing   BION-1301 dose-dependently and durably reduced IgA and IgM, and to a lesser extent, IgG, providing a pharmacodynamic (PD) window to potentially exploit reductions in IgA while

  • – Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy – Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, Including $25 Million in Additional Investment Committed by Chinook’s Existing Investors – Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months – Companies to H

  • When the transaction is completed, the combined company is expected to have about $200 million in cash, cash equivalents and marketable securities at closing.
  • Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host a live conference call and webcast on Monday, June 8, 2020 at 1:00 pm PDT to report data in healthy volunteers from the

  • Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2020.

  • Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2019. “2019 was a critical year for Adu

  • BERKELEY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the Cowen and Company 40 th Annual Health Care Conference in Boston, Massachusetts on Monday, March 2, 2020 at 12:00 pm ET.  To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor section of Aduro's website at

  • BERKELEY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 9 th Annual SVB Leerink Global Healthcare Conference in New York, New York on Wednesday, February 26, 2020 at 9:00 am ET.  To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor section of Aduro's website at

  • Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.
  • Aduro Biotech, Inc. announced that the company earned a $10.0 million development milestone payment under its worldwide licensing agreement with Merck for the initiation of a Phase 2 clinical trial of MK-5890, an anti-CD27 agonist, in non-small cell lung cancer.

  • As is often the case at the beginning and end of the year, a number of companies announced layoffs. Other news is related to lawsuits and an overall positive story about cancer death rates. Here’s a look.
  • The reduction in ongoing operating expenses is expected to extend the Company’s cash runway.

  • Aduro Biotech, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2019.

  • Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.